HBM Healthcare Investments AG (HBMN) Fair Value & Analysis
Financial Services · CH · Market cap CHF 1.7B
Fair value as of: Jul 16, 2026
From 11 valuation models · updated 16 days ago
Fair value updated Jul 16, 2026, revised from CHF 47.67 to CHF 390.41 (+719.0%) since Jun 26, 2026. Share price +5.7% over the past month.
A strong business, screening 56% undervalued on our models.
What matters now
- The rarer combination: high quality (81/100) AND below fair value. That earns a closer look rather than a quick verdict.
- The price is below even our cautious bear case (CHF 292.81). The market is more pessimistic than our downside scenario.
- For a financial, book-value and earnings-based methods matter more than a cash-flow DCF, which fits banks and insurers poorly.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 16, 2026.
How to read this chart
60‑month range CHF 129.20 – CHF 298.16 · fair‑value band CHF 292.81 – CHF 488.02 · the CHF 250.50 price screens below the CHF 390.41 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 16, 2026.
Analysis
HBM Healthcare Investments AG (HBMN) currently trades at CHF 250.50, while our model-based Fair Value estimate is CHF 390.41, implying the stock looks roughly 55.9% undervalued today. We read business quality at 81/100 (high quality), in the Financial Services sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, HBM Healthcare Investments AG generated revenue of CHF 276M at a net margin of 98.6%. It earns a return on equity of 15.6%. Net debt stands at CHF 94.3M. The stock trades on a trailing P/E of 5.8. Fundamentals as of Jul 16, 2026
Our scenario range runs from CHF 292.81 (bear case) to CHF 488.02 (bull case); at CHF 250.50, the current price sits below that range. The share trades near its 52-week high and 59% above its 52-week low, currently above its 200-day average. For context, the median of 10 Financial Services peers we cover trades at -51% fair-value upside, at 56%, HBMN screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 11 models by family
Widest divergence: Growth Earnings (CHF 1,854) versus Dividend Discount (CHF 62.91). Highest evidence: Residual Income (76).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 16, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 69 · Market factors (momentum, volatility) 79
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
HBM Healthcare Investments AG specializes in fund of funds and direct investments in middle market and mature companies.
Full company description
HBM Healthcare Investments AG specializes in fund of funds and direct investments in middle market and mature companies. The fund prefers to invest in start up, early stage, mid stage, mid venture, late venture, and late stage private companies, unlisted emerging companies, small cap public companies, buyouts, growth capital, and private investment in public equities (PIPES). Within fund of funds, it invests in venture capital funds. It also seeks to finance spin-offs of product lines or departments from larger corporations and the expansion or restructuring of established companies, seed stages, venture capital, expansion capital stages, spin-offs, and buyouts. The fund prefers to invest in the private and public companies in the healthcare sector with a focus on human medicine, drugs, pharma , biopharma, biotechnology, diagnostics, medical technology, and related industries. It seeks to make initial investments in companies whose primary products are in clinical development or the immediately preceding stage. The fund typically invests globally with a focus on Asia Pacific, Asia, North America, and Europe. In case of public companies, it focuses on those which originate from its private portfolio. The fund increases its investment in portfolio companies by participating in a follow-on financing or after the portfolio company's IPO. It may acquire majority participations in portfolio companies, usually takes a seat on the portfolio company's Board of Directors, and largely makes equity investments but may also invest through other instruments including convertible bonds, debt securities, structured products, and derivatives. The fund exits its portfolio companies through trade sale or IPO.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
HBM Healthcare Investments AG reported revenue of CHF 274M in FY2026 versus −CHF 76.5M in FY2022. Reported net income was CHF 272M in FY2026.
Watch HBMN: get an alert when its fair value changes →
Peer Group
Asset Management · 995 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Asset Management median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Asset Management stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Fondul Proprietatea SA FP | $0.0420 | $0.0800 | +90% |
| BlackRock, Inc BLK | $1,036 | $504.81 | -51% |
| Blackstone Inc BX | $124.56 | $16.35 | -87% |
| Investor AB INVEB | kr 394.40 | kr 788.80 | +100% |
| Brookfield Corporation BN | $41.21 | $9.95 | -76% |
| KKR & Co KKR | $100.94 | $44.88 | -56% |
| AB Industrivärden INDUA | kr 532.50 | kr 1,065 | +100% |
| Jio Financial Services Limited JIOFIN | ₹242.98 | ₹40.19 | -83% |
| Bajaj Holdings BAJAJHLDNG | ₹10,398 | ₹9,202 | -12% |
| HDFC Asset Management Company HDFCAMC | ₹2,729 | ₹301.41 | -89% |
Compare HBM Healthcare Investments AG with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Financial Services stocks →
Frequently asked questions
Is HBM Healthcare Investments AG (HBMN) overvalued or undervalued?
What is the fair value of HBMN?
What is the quality score of HBMN?
What is the revenue of HBM Healthcare Investments AG (HBMN)?
What is the net profit margin of HBMN?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track HBM Healthcare Investments AG and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.